Phase 1/2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Patients With Age-Related Macular Degeneration

Inclusion Criteria include, but are not limited to: * Diagnosed with sub-foveal choroidal neovascularization secondary to age-related macular degeneration * Visual acuity of 20/50 to 20/200 in study eye Exclusion Criteria: * Any other ocular disease that could compromise vision in the study eye * History of any prior treatment for choroidal neovascularization in the study eye * Presence of other causes of choroidal neovascularization other than secondary to age-related macular degeneration